RayzeBio nets over $100 million in Series C financing

By AuntMinnie.com staff writers

June 15, 2021 -- Radiopharmaceutical startup RayzeBio has received $108 million in Series C financing to support its development of targeted radiopharmaceuticals for cancer treatment.

The financing round was led by Venrock Healthcare Capital Partners, along with new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X, according to RayzeBio. In addition, all of Rayze's existing investors participated, including venBio Partners, Versant Venture, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others, the company said.

RayzeBio has now raised a total of $258 million since launching in August 2020.

Copyright © 2021 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking